Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data
Adagrasib/Keytruda Show Preliminary ORR Of 71%
The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.
You may also be interested in...
Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?
Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.
Mirati’s New CEO Clears Out Execs Ahead Of Key Filing And Readout
The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.
Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.